Bone Biologics (BBLG) Net Cash Flow (2012 - 2025)
Bone Biologics (BBLG) reported Net Cash Flow of -$700000.0 for Q4 2025, down 190.1% year-over-year from $776903.1 in Q4 2024, and down 16.67% quarter-over-quarter from -$600000.0 in Q3 2025.
Bone Biologics (BBLG) Net Cash Flow (2012 - 2025) Analysis & Trends
Bone Biologics (BBLG) has 14 years of Net Cash Flow data on file, last reported at -$700000.0 in Q4 2025.
- Net Cash Flow for Q4 2025 came in at -$700000.0, down 190.1% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.0 million (up 569.99% YoY), and the FY2025 annual result was $2.0 million, up 569.99% from the prior year.
- Net Cash Flow eased to -$700000.0 in Q4 2025 per BBLG's latest filing, from -$600000.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $6.7 million in Q4 2021 and troughed at -$3.6 million in Q2 2023.
- A 5-year average of -$177827.6 and a median of -$473865.0 in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2021 and 2022: Net Cash Flow jumped 271208.94% in 2021, then plunged 37050.28% in 2022.
- A 5-year view of Net Cash Flow shows it stood at $6.7 million in 2021, then plunged by 129.24% to -$2.0 million in 2022, then rose by 26.9% to -$1.4 million in 2023, then jumped by 83.08% to -$241295.0 in 2024, then sank by 190.1% to -$700000.0 in 2025.
- Business Quant data shows BBLG's Net Cash Flow at -$700000.0 in Q4 2025, -$600000.0 in Q3 2025, and $3.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 664,983.53 |
| 10 | Bone Biologics | 1.47 Mn | 1.47 Mn | - | -700,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -700,000.00 |
| Dec 31, 2025 | -700,000.00 |
| Sep 30, 2025 | -600,000.00 |
| Sep 30, 2025 | -600,000.00 |
| Jun 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 3.85 Mn |
| Mar 31, 2025 | -552,451.00 |
| Mar 31, 2025 | -552,451.00 |
| Dec 31, 2024 | -241,295.00 |
| Dec 31, 2024 | -241,295.00 |
| Sep 30, 2024 | 1.23 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Jun 30, 2024 | -895,566.00 |
| Jun 30, 2024 | -895,566.00 |
| Mar 31, 2024 | 201,065.00 |
| Mar 31, 2024 | 201,065.00 |
| Dec 31, 2023 | -1.43 Mn |
| Dec 31, 2023 | -1.43 Mn |
| Sep 30, 2023 | -2.56 Mn |
| Sep 30, 2023 | -2.56 Mn |